Reported Saturday, Black Diamond Therapeutics Showcased BDTX-1535 Clinical Data In Patients With Recurrent Glioblastoma At 2024 ASCO Annual Meeting

6/3/24 3:47:08 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $BDTX alert in real time by email

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment

Initial data from Phase 0/1 "trigger" ("window of opportunity") investigator-sponsored trial demonstrated BDTX-1535 achieved clinically meaningful drug levels in brain tumor tissue

Get the next $BDTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BDTX

Date	Price Target	Rating	Analyst
7/31/2024	$20.00	Outperform	Raymond James
7/14/2023		Overweight	Piper Sandler
6/30/2023	$2.00 → $10.00	Hold → Buy	Stifel
6/28/2023	$11.00	Neutral → Buy	H.C. Wainwright
6/27/2023	$10.00	Neutral → Outperform	Wedbush
3/29/2022		Outperform → Neutral	Wedbush
3/22/2022		Buy → Neutral	H.C. Wainwright
9/30/2021	$10.00	Hold	Stifel

More analyst ratings

$BDTX
Press Releases

Fastest customizable press release news feed in the world

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024 Presented real-world treatment practices and patient outcomes in newly diagnosed NSCLC patients with non-classical EGFR mutations at the 2024 ESMO Congress Clinical updates of BDTX-1535 in EGFRm NSCLC and regulatory feedback expected in Q1 2025Cash, cash equivalents, and investments of $112.7 million as of September 30, 2024; expected to be sufficient to fund operations into Q2 of 2026 CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-st
11/5/24 8:00:00 AM ET
$BDTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: Stifel Healthcare Conference fireside chat at 4:10pm ET on Tuesday, November 19, 2024Piper Sandler 36th Annual Healthcare Conference fireside chat at 3:00pm ET on Wednesday, December 4, 2024 Webcasts will be available at the start of the presentations on the investor relations section
11/1/24 8:00:00 AM ET
$BDTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-4933 and seek potential partners Anticipated cost savings expected to extend cash runway into Q2 2026 CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, announced today a corporate restructuring to focus resources on advancing lead program BDTX-1535 into pivotal development, and to extend the Company's expected cash runway into Q2 2026. BDTX-1535 has demonstrated robust Phase 2 clinical activity acros
10/7/24 4:01:00 PM ET
$BDTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$BDTX
Leadership Updates

Live Leadership Updates

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be
8/8/24 4:05:00 PM ET
$BDTX
$GYRE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Black Diamond Therapeutics Announces Changes to Board of Directors
CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancers, today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company's Board of Directors. The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors. These changes became effective as of April 10, 2024. "On behalf of the board, I am excited to welcome Shannon and Prakash, both seasoned executives who bring deep and highly relevant oncolog
4/11/24 8:00:00 AM ET
$BDTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBDTX-1535 NSCLC expansion cohorts enrolling, initial data expected in 2024BDTX-1535 Phase 1 dose escalation data in GBM expected later this yearDosed first patient in a Phase 1 trial of BDTX-4933, a brain-penetrant RAF inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors Cash, cash equivalents, and investments of $144.3 million as of September 30, 2023, expected to be sufficient to fund operations into the fir
11/6/23 7:45:00 AM ET
$BDTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Reported Saturday, Black Diamond Therapeutics Showcased BDTX-1535 Clinical Data In Patients With Recurrent Glioblastoma At 2024 ASCO Annual Meeting

Chat with this insight

Recent Analyst Ratings for $BDTX

$BDTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Raymond James initiated coverage on Black Diamond Therapeutics with a new price target

Piper Sandler initiated coverage on Black Diamond Therapeutics

Black Diamond Therapeutics upgraded by Stifel with a new price target

$BDTX Press Releases

Fastest customizable press release news feed in the world

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

$BDTX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Biotech Growth N V bought $934,080 worth of shares (400,000 units at $2.34), increasing direct ownership by 5% to 8,517,839 units (SEC Form 4)

$BDTX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Black Diamond Therapeutics Inc.

SEC Form SC 13G filed by Black Diamond Therapeutics Inc.

Amendment: SEC Form SC 13D/A filed by Black Diamond Therapeutics Inc.

$BDTX Leadership Updates

Live Leadership Updates

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

Black Diamond Therapeutics Announces Changes to Board of Directors

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

$BDTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$BDTX Market Insights

Live Market Insights

$BDTX SEC Filings

Director Behbahani Ali was granted 3,007 shares, increasing direct ownership by 6% to 57,584 units (SEC Form 4)

Director Campbell Shannon was granted 2,354 shares, increasing direct ownership by 117% to 4,365 units (SEC Form 4)

Director Raman Prakash was granted 2,694 shares, increasing direct ownership by 117% to 4,995 units (SEC Form 4)

Piper Sandler Maintains Overweight on Black Diamond Therapeutic, Maintains $12 Price Target

12 Health Care Stocks Moving In Tuesday's Intraday Session

HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target

SEC Form 10-Q filed by Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Black Diamond Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

$BDTX Financials

Live finance-specific insights

Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

Recent Analyst Ratings for
$BDTX

$BDTX
Analyst Ratings

$BDTX
Press Releases

$BDTX
Insider Purchases

$BDTX
Large Ownership Changes

$BDTX
Leadership Updates

$BDTX
Insider Trading

$BDTX
Market Insights

$BDTX
SEC Filings

$BDTX
Financials